A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms U-EXCEL
- Sponsors AbbVie; AbbVie Germany
- 17 Oct 2023 Results of a pooled analysis assessing effect of UPA treatment on extraintestinal manifestations in patients in induction and maintenance studies: U-EXCEL, U-EXCEED and U-ENDURE presented at the 31st United European Gastroenterology Week
- 17 Oct 2023 Results of pooled analysis ( from studies NCT03345849,NCT03345836, and NCT03345823) assessing efficacy and safety of upadacitinib for patients with Crohns disease presented at the 31st United European Gastroenterology Week
- 17 Oct 2023 Results of post hoc analysis (n=204) assessing the efficacy and safety of UPA in the induction treatment of East Asian patients presented at the 31st United European Gastroenterology Week